Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy.
Antibody-drug conjugate (ADC), a novel class of antineoplastic agents, combines tumor-specific targeting with potent cytotoxic activity. In recent years, ADC has achieved notable advances in the treatment of non-small cell lung cancer (NSCLC), particularly within therapeutic sequencing after failure...
| Publicado en: | Chinese Journal of Lung Cancer Vol. 28; no. 9; pp. 710 - 721 |
|---|---|
| Autores principales: | , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Chinese Journal of Lung Cancer
Sep2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |